Phil Pang, M.D., Ph.D.

Executive Vice President, Chief Medical Officer and Interim Head of Research

Phil Pang, M.D., Ph.D., has served as Vir’s Executive Vice President, Chief Medical Officer, and Interim Head of Research since July 2022. He is responsible for the Company’s global clinical development portfolio. Dr. Pang’s industry career has been dedicated to the development of novel therapies to address some of the world’s most challenging infectious diseases. Since joining Vi in 2016, Dr. Pang has advanced numerous compounds from early-to late-stage clinical development, including sotrovimab, a monoclonal antibody treatment for COVID-19.

Prior to Vir, Dr. Pang served as Chief Medical Officer of Riboscience LLC, a Roche-spinoff developing small molecule antivirals. Previously, during his four-year tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrix team to the successful worldwide approval of the first one-pill, once-a-day hepatitis C treatment.

Dr. Pang received a B.S. in biological sciences from Stanford University and a Ph.D. in biochemistry and biophysics from Columbia University. He obtained his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed his fellowship in infectious diseases at Stanford University.